Welcome to the international HTA database

Showing [24014 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2024	NIHR Health and Social Care Delivery Program	Chair-based yoga programme for older adults with multimorbidity: RCT with embedded economic and process evaluations
2024	Ontario Health	Level 2 polysomnography for the diagnosis of sleep disorders
2024	NIHR Health Technology Assessment programme	Cervical ripening at home or in hospital during induction of labour: the CHOICE prospective cohort study, process evaluation and economic analysis
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Chronic graft-versus-host disease; assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2024	NIHR Health Technology Assessment programme	The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024	NIHR Health and Social Care Delivery Program	The UK resuscitative endovascular balloon occlusion of the aorta in trauma patients with life-threatening torso haemorrhage: the (UK-REBOA) multicentre RCT
2024	Ontario Health	Pelvic floor muscle training for stress urinary incontinence, fecal incontinence, and pelvic organ prolapse
2024	NIHR Health Services and Delivery Research programme	Clinical and cost-effectiveness of first contact physiotherapy for musculoskeletal disorders in primary care: the FRONTIER, mixed method realist evaluation
2024	NIHR Health and Social Care Delivery Program	Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT
2024	Haute Autorite de sante (HAS)	[Targeted next generation sequencing gene panel in the medical management of chronic lymphocytic leukemia]
2024	NIHR Health Services and Delivery Research programme	A model of occupational stress to assess impact of COVID-19 on critical care and redeployed nurses: a mixed-methods study
2024	NIHR Health and Social Care Delivery Program	Improving the integration of care for trans adults: ICTA a mixed-methods study
2024	WorkSafeBC	Efficacy/effectiveness of prolotherapy in treating wrist sprain/strain or repetitive strain injury (RSI)
2024	NIHR Health Technology Assessment programme	Energetic activity for depression in young people aged 13–17 years: the READY feasibility RCT
2024	NIHR Health and Social Care Delivery Program	Understanding and using experiences of social care to guide service improvements: translating a co-design approach from health to social care
2024	WorkSafeBC	Causal association in developing breast cancer among female firefighters
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: blood cortisol and dexamethasone measurements using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in the context of a dexamethasone suppression test]
2024	Agency for Care Effectiveness (ACE)	Wingspan stent system for intracranial atherosclerotic stenosis
2024	NIHR Health Technology Assessment programme	Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT
2024	NIHR Health and Social Care Delivery Program	The Resilience Hub approach for addressing mental health of health and social care workers during the COVID-19 pandemic: a mixed-methods evaluation
2024	WorkSafeBC	Causal association on the development of trigeminal neuralgia post covid-19 vaccine
2024	HTA Region Stockholm	[Benefits and harms of intra-articular corticosteroid injections for hip osteoarthritis]
2024	Agency for Care Effectiveness (ACE)	Cochlear implants for children with single-sided deafness
2024	NIHR Health Technology Assessment programme	Devices for remote continuous monitoring of people with Parkinson’s disease: a systematic review and cost-effectiveness analysis
2024	Penn Medicine Center for Evidence-based Practice (CEP)	Urinary catheterization for epidural anesthesia in obstetrics
2024	WorkSafeBC	Efficacy/effectiveness of brain mapping in treating concussions
2024	HTA Region Stockholm	[Effectiveness and safety of intense pulsed light therapy for dry eye symptoms due to meibomian gland dysfunction]
2024	NIHR Health Technology Assessment programme	A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model
2024	NIHR Health and Social Care Delivery Program	Interventions to minimise hospital winter pressures related to discharge planning and integrated care: a rapid mapping review of UK evidence
2024	WorkSafeBC	Effectiveness of prolotherapy in shoulder labral tears
2024	National Institute for Health and Care Excellence (NICE)	Tirzepatide for managing overweight and obesity. NICE technology appraisal guidance 1026
2024	NIHR Health Technology Assessment programme	Home-monitoring for neovascular age-related macular degeneration in older adults within the UK: the MONARCH diagnostic accuracy study
2024	WorkSafeBC	Causal association between firefighting and pulmonary fibrosis
2024	National Institute for Health and Care Excellence (NICE)	Ublituximab for treating relapsing multiple sclerosis. NICE technology appraisal guidance 1025
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lebrikizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V]
2024	NIHR Health Technology Assessment programme	Reducing self-harm in adolescents: the RISA-IPD individual patient data meta-analysis and systematic review
2024	NIHR Health and Social Care Delivery Program	Women’s Health Hubs: a rapid mixed-methods evaluation
2024	WorkSafeBC	Causal association between soft tissue injury/trauma and aggravation of CRPS
2024	National Institute for Health and Care Excellence (NICE)	Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1023
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: expressing wishes regarding goals of care and the decision about cardiopulmonary resuscitation]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Zanubrutinib (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Newsletter: integrating innovations into social and health services systems]
2024	NIHR Health and Social Care Delivery Program	Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT
2024	WorkSafeBC	Efficacy/effectiveness of Cryoderm Cooling Gel®/Ligament Restore Supplement in treating lumbar sprain/strain
2024	National Institute for Health and Care Excellence (NICE)	Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal). NICE technology appraisal guidance 1024
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Rucaparib (maintenance treatment in ovarian cancer after first-line therapy) – Benefit assessment according to §35a Social Code Book V]
2024	NIHR Health and Social Care Delivery Program	Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model
2024	WorkSafeBC	Effectiveness of extra corporeal shockwave therapy (ESWT) in treating shoulder labral tears
2024	National Institute for Health and Care Excellence (NICE)	Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1021
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lanadelumab (hereditary angioedema, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V]
2024	NIHR Health and Social Care Delivery Program	Initial assessment and management of adults with suspected acute respiratory infection: a rapid evidence synthesis of reviews and cost-effectiveness studies
2024	WorkSafeBC	Effectiveness of platelet rich plasma therapy (PRP) in treating shoulder labral tears
2024	National Institute for Health and Care Excellence (NICE)	Bevacizumab gamma for treating wet age-related macular degeneration. NICE technology appraisal guidance 1022
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alirocumab (hypercholesterolaemia) – Benefit assessment according to §35a Social Code Book V]
2024	NIHR Health Services and Delivery Research programme	The consequences of micro-discretions and boundaries in the social prescribing link worker role in England: a realist evaluation
2024	WorkSafeBC	Effectiveness of extra corporeal shockwave therapy (ESWT) in treating costochondritis and soft tissue contusion: 2024 update
2024	National Institute for Health and Care Excellence (NICE)	MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's. NICE interventional procedures guidance 796
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Letermovir (CMV prophylaxis after kidney transplant) – Benefit assessment according to §35a Social Code Book V]
2024	NIHR Health Services and Delivery Research programme	Health visiting in the UK in light of the COVID-19 pandemic experience: (RReHOPE) findings from a realist review
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: blood quantification of ruxolitinib by high-performance liquid chromatographytandem mass spectrometry (HPLC-MS/MS)]
2024	National Institute for Health and Care Excellence (NICE)	MRI-guided focused ultrasound subthalamotomy for treating Parkinson's. NICE interventional procedures guidance 797
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V]
2024	Health Information and Quality Authority (HIQA)	Health technology assessment of providing an alternative telephone pathway for acute, non-urgent medical care needs in the pre-hospital setting
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism by MS/MS. Update and assessment regional programs. Methylmalonic acidemias; Propionic acidaemia]
2024	National Institute for Health and Care Excellence (NICE)	Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. NICE interventional procedures guidance 795
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Letermovir (CMV prophylaxis after stem cell transplantation) – Benefit assessment according to §35a Social Code Book V]
2024	Institute for Clinical Effectiveness and Health Policy (IECS)	[Artificial urinary sphincter in pediatric patients]
2024	National Institute for Health and Care Excellence (NICE)	Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome. NICE diagnostics guidance 62
2024	NIHR Health Technology Assessment programme	Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V]
2024	NIHR Health and Social Care Delivery Program	Meeting social welfare legal needs in end-of-life care: co-creation of a system-wide research partnership
2024	Scottish Health Technologies Group (SHTG)	Green theatres
2024	NIHR Health Technology Assessment programme	Effectiveness of septoplasty compared to medical management in adults with obstruction associated with a deviated nasal septum: the NAIROS RCT
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone for DLBCL – Benefit assessment according to § 35a Social Code Book V]
2024	Belgian Health Care Knowledge Centre (KCE)	Budget impact projections for pharmaceuticals
2024	Austrian Institute for Health Technology Assessment (AIHTA)	[Liposuction for the removal of subcutaneous (large) lipomas]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: an overview of emergency department visits and hospitalizations among young people aged 6 to 25 for mental health and psychosocial issues in 2022–2023, compared to the pre-pandemic (2016–2020) and pandemic periods (2020–2022) of COVID-19]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2024	Austrian Institute for Health Technology Assessment (AIHTA)	Role of public contributions to the development of health innovations and its integration in value assessment and pricing/reimbursement decisions
2024	The Danish Health Technology Council (DHTC)	[Assessment of non-surgical treatment of distal radius fractures in patients older than 65 years]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: genital herpes - identification, diagnosis, optimal use of antivirals and follow-up]
2024	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Point-of-care ultrasound for the evaluation of pulmonary volume overload in an outpatient setting]
2024	Austrian Institute for Health Technology Assessment (AIHTA)	[Biomarkers in Parkinson's Disease]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: a brief overview of indicators for care and service transitions of community-dwelling seniors with major neurocognitive disorder (MNCD) in Quebec]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) – Benefit assessment according to §35a Social Code Book V]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: syndromic approach - pharmacological treatment]
2024	Austrian Institute for Health Technology Assessment (AIHTA)	[Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Measurement and monitoring of pulmonary arterial pressure by means of implanted sensor for treatment optimization in heart failure stage NYHA III]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (gastric cancer, HER2-negative) – Benefit assessment according to §35a Social Code Book V]
2024	Institute for Clinical Effectiveness and Health Policy (IECS)	[Stereotactic radiosurgery in benign tumors of the central nervous system]
2024	Basque Office for Health Technology Assessment (OSTEBA)	[Exoskeletons for the functional recovery of walking ability in patients with central nervous system disorders such as multiple sclerosis, stroke, and traumatic spinal injury]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cannabidiol (Lennox Gastaut syndrome) – Benefit assessment according to §35a Social Code Book V]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (biliary cancer) – Benefit assessment according to §35a Social Code Book V]
2024	Norwegian Institute of Public Health (NIPH)	[Cost-effectiveness of robot assisted surgery for prostate cancer]
2024	Basque Office for Health Technology Assessment (OSTEBA)	[Use of self-sampling for the detection of human papillomavirus in cervical cancer screening]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Palopegteriparatide (chronic hypoparathyroidism) – Benefit assessment according to §35a Social Code Book V]
2024	NIHR Health and Social Care Delivery Program	Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Vosoritide (achondroplasia, ≥ 4 months) – Benefit assessment according to §35a Social Code Book V]